The trial aimed to evaluate the feasibility of telemedicine in monitoring patients undergoing CAR-T therapy for relapsed or refractory large B-cell lymphoma. Given the increasing adoption of telehealth solutions, especially post-COVID-19, this approach could enhance patient management and reduce healthcare costs. However, the trial was withdrawn, indicating potential challenges in execution or strategic alignment. The market for CAR-T therapies is expanding, with significant competition from established players and emerging biotech firms. Companies should consider the implications of telemedicine integration in their CAR-T programs to improve patient outcomes and operational efficiencies.